- Greek Exit Could Trigger 50% Fall in Euro Stocks: Analyst
- Big Stock Upside for Hudson City Deal: Analyst
- 5 High-Yield Stocks Ready to Boost Dividends
- Option Bulls Take Another Shot on Idenix
- Top 20 European Stocks for Crisis Time: Strategist
- Hewlett-Packard Faces a ‘Dogfight’ for Talent: Analyst
- DuckDuckGo Cooks Google’s Goose: Analyst
- General Electric’s $4.5 Billion Dividend Slated for Buybacks
ABOUT THE CNBC STOCK BLOG
ART CASHIN
RSS FEED
CNBC Stock Blog
Text Size 
A Beaker Full Of Biotech Stocks
Sarat Sethi of Douglas C. Lane & Associates thinks investors ought to buy stocks, but must choose very carefully before they do.
"I think it's too early to get into areas where companies are too levered, because capital markets are still not fully open," he told CNBC. "I would stick with the consumer staples, companies that have good international diversification, and health care, especially life sciences and medical products."
Recommendations:
The medical-products field is his entry point into biotechnology.
"The way you play biotech is, you play the companies they use; if they're going to use a beaker that costs a hundred grand, you buy the companies that produce the equipment," he said.
"You buy companies like Millipore [MIL
Loading...
()
] or Qiagen [QGEN
Loading...
()
], where you know their products are going to be used across a wide range of biopharma industries."
Disclosures:
Disclosure information for Sarat Sethi was not immediately available.
JeeYeon Park contributed to this article.
Data is a real-time snapshot *Data is delayed at least 15 minutes
